except that all absorbed sera were held at 4 to 6 C for 16 to 24 hr before testing, to permit both qualitative and quantitative testing on the same batch of absorbed serum. All sera were tested by the qualitative procedure at a 1:80 final serum dilution; sera giving a reaction of one plus or greater were then tested quantitatively by use of serial twofold dilutions from 1:80 through 1:2,560. Quantitative tests were then repeated on a second day to measure reproducibility.
A passive hemagglutination test for syphilis in which an antigen derived from the virulent Nichols strain of Treponema pallidum is used has been described by Rathlev (6) and by Tomizawa and associates (7, 8) . This test was adapted to an automated microhemagglutination procedure by Cox et al. (1) , and in evaluations to date the automated procedure has yielded results comparable to those obtained with the fluorescent treponemal antibody-absorption (FTA-ABS) tests for syphilis (2, 4) . Because a reliable hemagglutination test would possess a considerable advantage in time and cost over the manually performed FTA-ABS test or the T. pallidum immobilization (TPI) test, an evaluation of the manual and automated microhemagglutination assay for T. pallidum antibodies (MHA-TP) was undertaken and is reported here.
In this study, sera from patients in clinically defined categories of syphilis were tested by the Venereal Disease Research Laboratory (VDRL) test, the FTA-ABS test, the TPI test, and the MHA-TP test to evaluate the sensitivity of the hemagglutination test in comparison with other treponemal and reagin tests. Sera from presumably nonsyphilitic individuals were tested as a measure of test specificity. All MHA-TP reactors were quantitated by an automated method to determine the applicability of this procedure in a diagnostic laboratory.
MATERIALS AND METHODS
Test procedure. The MHA-TP test was performed according to the provisional technique (11) except that all absorbed sera were held at 4 to 6 C for 16 to 24 hr before testing, to permit both qualitative and quantitative testing on the same batch of absorbed serum. All sera were tested by the qualitative procedure at a 1:80 final serum dilution; sera giving a reaction of one plus or greater were then tested quantitatively by use of serial twofold dilutions from 1:80 through 1:2,560. Quantitative tests were then repeated on a second day to measure reproducibility.
The FTA-ABS and VDRL tests were performed 26 according to the published techniques (9) . The TPI test was performed as in the described procedure (10) with the following exceptions: undiluted guinea pig complement was used instead of 200 hemolytic units; results were reported as reactive with greater than 60% immobilization, weakly reactive with 30 to 59%, inconclusive with 18 to 29%, and nonreactive with less than 18% immobilization.
Reagents. Reagents for many of the MHA-TP tests were generously supplied by Canalco, Inc. Antigen for the FTA-ABS test was prepared in this laboratory (12) In the evaluation reported here, the MHA-TP test compared favorably with the TPI and FTA-ABS tests in all stages of syphilis except primary syphilis, in which it was less sensitive than the FTA-ABS test and possibly less sensitive than the TPI test. Other investigators have also noted a lack of sensitivity in the hemagglutination test in primary syphilis (2, 3, 8) . In a recent field study of the MHA-TP test, the three participating laboratories reported MHA-TP reactivities in primary syphilis of 92.5% on 134 sera, 75% on 32 sera, and 94.7% on 19 sera (2) . These MHA-TP results show a higher percentage of reactivity than the 64% found in our laboratory, but the FTA-ABS test was also more reactive in the other laboratories, suggesting a difference in the infection status of the patient groups categorized as primary syphilis. More information is needed on the dynamics of antibody detection by the various treponemal tests in first-infection pri- The value of quantitative MHA-TP results is not resolved. Certain trends are evident in the various categories of syphilis, but information on the reactivity of sera from individual patients over a period of time is needed to evaluate this procedure fully. The few patients' sera that we examined in this way suggest that MHA-TP titer movement parallels that of the FTA-ABS test, in that the titer response to treatment is slower and less pronounced than in the VDRL test.
The specificity of the MHA-TP test was good, with a specificity of 98.8% on BFP sera. In the presumed normal group, the reactivity of the MHA-TP was only 0.9%, and all MHA-TP reactive sera were also reactive in the FTA-ABS test.
The reproducibility of the automated quantitative MHA-TP test was satisfactory. The poorest reproducibility was obtained when sera reacting minimally in the qualitative test were retested quantitatively. Many of these sera yielded weak nonspecific agglutination of control cells upon retesting rather than negative reactions. These results suggest that good laboratory practice would encompass the retesting of all one and two plus qualitative reactors before results are reported.
Because of the apparent lack of sensitivity of the MHA-TP test in primary syphilis, we would hesitate to use this test as the only treponemal procedure at this stage of its development. However, it could provide a very useful tool in conjunction with the VDRL test or another reagin test to eliminate a large number of the FTA-ABS tests now required. A reaction in both the reagin and MHA-TP tests would indicate syphilis, and no further testing would be required. Reagin reactive, MHA-TP nonreactive sera would require FTA-ABS testing.
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